{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:14:27Z","timestamp":1790399667704,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R43 MH067488-01"],"award-info":[{"award-number":["R43 MH067488-01"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00213-016-4346-2","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T20:23:38Z","timestamp":1466886218000},"page":"3113-3124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats"],"prefix":"10.1007","volume":"233","author":[{"given":"Gretchen L.","family":"Snyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Prickaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Wadenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Hendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"Wennogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"4346_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.tics.2006.08.003","volume":"10","author":"JP Aggleton","year":"2006","unstructured":"Aggleton JP, Brown MW (2006) Interleaving brain systems for episodic and recognition memory. Trends Cogn Sci 10:455\u2013463","journal-title":"Trends Cogn Sci"},{"key":"4346_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbr.2012.03.022","volume":"232","author":"S Akkerman","year":"2012","unstructured":"Akkerman S, Blokland A, Reneerkens O, van Goethem NP, Bollen E, Gijselaers HJ, Lieben CK, Steinbusch HW, Prickaerts J (2012a) Object recognition testing: methodological considerations on exploration and discrimination measures. Behav Brain Res 232:335\u2013347","journal-title":"Behav Brain Res"},{"key":"4346_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bbr.2012.03.024","volume":"232","author":"S Akkerman","year":"2012","unstructured":"Akkerman S, Prickaerts J, Steinbusch HW, Blokland A (2012b) Object recognition testing: statistical considerations. Behav Brain Res 232:317\u2013322","journal-title":"Behav Brain Res"},{"key":"4346_CR4","doi-asserted-by":"crossref","unstructured":"Akkerman S, Prickaerts J, Bruder AK, Wolfs KH, De Vry J, Vanmierlo T, Blokland A (2014) PKE5 inhibition improves object memory in standard housed rats but not in rats housed in an enriched environment: implications for memory models? PLoS One 9(11) e111692","DOI":"10.1371\/journal.pone.0111692"},{"key":"4346_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuropharm.2015.04.019","volume":"97","author":"S Akkerman","year":"2015","unstructured":"Akkerman S, Blokland A, van Goethem NP, Cremers P, Shaffer CL, Osgood SM, Steinbusch HW, Prickaerts J (2015) PDE5 inhibition improves acquisition processes after learning via a central mechanism. Neuropharmacology 97:233\u2013239","journal-title":"Neuropharmacology"},{"key":"4346_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1101\/lm.040162.115","volume":"23","author":"S Akkerman","year":"2016","unstructured":"Akkerman S, Blokland A, Prickaerts J (2016) Possible overlapping time frames of acquisition and consolidation phases in object memory processes: a pharmacological approach. Learn Mem 23:29\u201337","journal-title":"Learn Mem"},{"key":"4346_CR7","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/rcm.2046","volume":"19","author":"NM Appels","year":"2005","unstructured":"Appels NM, van Maanen MJ, Rosing H, Schellens JH, Beijnen JH (2005) Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2187\u201392","journal-title":"Rapid Commun Mass Spectrom"},{"key":"4346_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","volume":"51","author":"J Arnt","year":"1982","unstructured":"Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51:321\u20139","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"4346_CR9","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1073\/pnas.95.25.15020","volume":"95","author":"M Barad","year":"1998","unstructured":"Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A 95:15020\u20135","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4346_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488\u2013520","journal-title":"Pharmacol Rev"},{"key":"4346_CR11","doi-asserted-by":"crossref","first-page":"18676","DOI":"10.1016\/S0021-9258(19)37014-0","volume":"267","author":"JK Bentley","year":"1992","unstructured":"Bentley JK, Kadlecek A, Sherbert CH, Seger D, Sonnenburg WK, Charbonneau H et al (1992) Molecular cloning of cDNA encoding a \"63\"-kDa calmodulin-stimulated phosphodiesterase from bovine brain. J Biol Chem 267:18676\u201382","journal-title":"J Biol Chem"},{"key":"4346_CR12","first-page":"85","volume-title":"Episolid Memory: Formation, Clinical Disorders and Role of Aging","author":"RM Berkers","year":"2014","unstructured":"Berkers RM, van Goethem N, Rutten Blokland A, Prickaerts J (2014) The medial temporal lobe: toward a unifying neuropsuchobiological framework of recognition and recall. In: Edison K (ed) Episolid Memory: Formation, Clinical Disorders and Role of Aging. Nova, Hauppauge NY, pp 85\u2013133"},{"key":"4346_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"FG Boess","year":"2004","unstructured":"Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081\u20131092","journal-title":"Neuropharmacology"},{"key":"4346_CR14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/npp.2014.106","volume":"39","author":"E Bollen","year":"2014","unstructured":"Bollen E, Puzzo D, Rutten K, Privitera L, De Vry J, Vanmierlo T, Kenis G, Palmeri A, D'Hooge R, Balschun D, Steinbusch HM, Blokland A, Prickaerts J (2014) Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. Neuropsychopharmacology 39:2497\u20132505","journal-title":"Neuropsychopharmacology"},{"key":"4346_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.neuropharm.2015.04.008","volume":"95","author":"E Bollen","year":"2015","unstructured":"Bollen E, Akkerman S, Puzzo D, Gulisano W, Palmeri A, D'Hooge R, Balschun D, Steinbusch HW, Blokland A, Prickaerts J (2015) Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors. Neuropharmacology 95:361\u2013366","journal-title":"Neuropharmacology"},{"key":"4346_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1101\/lm.5.4.365","volume":"5","author":"R Bourtchouladze","year":"1998","unstructured":"Bourtchouladze R, Abel T, Berman N, Gordon R, Lapidus K, Tully T (1998) Different training procedures recruit either one of two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn Mem 5:365\u201374","journal-title":"Learn Mem"},{"key":"4346_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10072-009-0033-y","volume":"30","author":"I Cancelli","year":"2009","unstructured":"Cancelli I, Beltrame M, Gigle GL, Valente M (2009) Drugs with anticholinergic properties : cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 30:87\u201392","journal-title":"Neurol Sci"},{"key":"4346_CR18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1126\/science.287.5460.2020","volume":"287","author":"SA Castner","year":"2000","unstructured":"Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287:2020\u20132022","journal-title":"Science"},{"key":"4346_CR19","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099\u2013108","journal-title":"Biochem Pharmacol"},{"key":"4346_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","volume":"76","author":"M Conti","year":"2007","unstructured":"Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481\u2013511","journal-title":"Annu Rev Biochem"},{"key":"4346_CR21","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.neubiorev.2012.03.003","volume":"37","author":"PA Dudchenko","year":"2013","unstructured":"Dudchenko PA, Talpos J, Young J, Baxter MG (2013) Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Neurosci Biobehav Rev 37:2111\u20132124","journal-title":"Neurosci Biobehav Rev"},{"key":"4346_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.neuro.30.051606.094328","volume":"30","author":"H Eichenbaum","year":"2007","unstructured":"Eichenbaum H, Yonelinas AP, Ranganath C (2007) The medial temporal lobe and recognition memory. Annu Rev Neurosci 30:123\u2013152","journal-title":"Annu Rev Neurosci"},{"key":"4346_CR23","first-page":"47","volume":"31","author":"A Ennaceur","year":"1988","unstructured":"Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res 31:47\u201359","journal-title":"Brain Res"},{"key":"4346_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00030.2010","volume":"91","author":"SH Francis","year":"2011","unstructured":"Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91:651\u201390","journal-title":"Physiol Rev"},{"key":"4346_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","volume":"174","author":"PS Goldman-Rakic","year":"2004","unstructured":"Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174:3\u201316","journal-title":"Psychopharmacology"},{"key":"4346_CR26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1176\/ajp.156.9.1336","volume":"156","author":"AL Hoff","year":"1999","unstructured":"Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE (1999) Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 156:1336\u201341","journal-title":"Am J Psychiatry"},{"key":"4346_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1023\/A:1020715800956","volume":"22","author":"LA Izquierdo","year":"2002","unstructured":"Izquierdo LA, Barros DM, Vianna MR, Coitinho A, deDavid e Silva T, Choi H, Moletta B, Medina JH, Izquierdo I (2002) Molecular pharmacological dissection of short- and long-term memory. Cell Mol Neurobiol 22:269\u2013287","journal-title":"Cell Mol Neurobiol"},{"key":"4346_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","volume":"70","author":"RS Kahn","year":"2013","unstructured":"Kahn RS, Keefe RS (2013) Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 70:1107\u20131112","journal-title":"JAMA Psychiatry"},{"key":"4346_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1756-6606-5-14","volume":"5","author":"ER Kandel","year":"2012","unstructured":"Kandel ER (2012) The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol Brain 5:14","journal-title":"Mol Brain"},{"key":"4346_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbr.2014.07.017","volume":"272","author":"S Karamihalev","year":"2014","unstructured":"Karamihalev S, Prickaerts J, van Goethem NP (2014) Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. Behav Brain Res 272:248\u2013251","journal-title":"Behav Brain Res"},{"key":"4346_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"V Lakics","year":"2010","unstructured":"Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367\u201374","journal-title":"Neuropharmacology"},{"key":"4346_CR32","first-page":"207","volume-title":"Introduction to Experimental Statistics","author":"CC Li","year":"1964","unstructured":"Li CC (1964) Introduction to Experimental Statistics. McGraw \u2013 Hill, New York, pp 207\u2013226"},{"key":"4346_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1021\/acs.jmedchem.5b01751","volume":"59","author":"P Li","year":"2016","unstructured":"Li P, Zheng H, Zhao J, Zhang L, Yao W, Zhu H, Beard JD, Ida K, Lane W, Snell G, Sogabe S, Heyser CJ, Snyder GL, Hendrick JP, Vanover KE, Davis RE, Wennogle LP (2016) Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases. J Med Chem 59:1149\u201364","journal-title":"J Med Chem"},{"key":"4346_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"4346_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","volume":"202","author":"T Nagai","year":"2009","unstructured":"Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 202:315\u2013328","journal-title":"Psychopharmacology"},{"key":"4346_CR36","doi-asserted-by":"publisher","first-page":"11079","DOI":"10.1073\/pnas.89.22.11079","volume":"89","author":"JW Polli","year":"1992","unstructured":"Polli JW, Kincaid RL (1992) Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc Natl Acad Sci U S A 89:11079\u201383","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4346_CR37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1523\/JNEUROSCI.14-03-01251.1994","volume":"14","author":"JW Polli","year":"1994","unstructured":"Polli JW, Kincaid RL (1994) Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci 14:1251\u201361","journal-title":"J Neurosci"},{"key":"4346_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0014-2999(97)01301-0","volume":"337","author":"J Prickaerts","year":"1997","unstructured":"Prickaerts J, Steinbusch HWM, Smits JFM, De Vente J (1997) Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur J Pharmacol 337:125\u2013136","journal-title":"Eur J Pharmacol"},{"key":"4346_CR39","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.2174\/1381612819666131216114240","volume":"20","author":"L Rajagopal","year":"2014","unstructured":"Rajagopal L, Massey BW, Huang M, Oyamada Y, Meltzer HY (2014) The novel object recognition test in rodents in relatin to cognitive impairment in schizophrenia. Curr Pharm Des 20:5104\u20135114","journal-title":"Curr Pharm Des"},{"key":"4346_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","volume":"202","author":"OA Reneerkens","year":"2009","unstructured":"Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202:419\u2013443","journal-title":"Psychopharmacology"},{"key":"4346_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.nlm.2005.09.002","volume":"85","author":"K Rutten","year":"2006","unstructured":"Rutten K, Prickaerts J, Blokland A (2006) Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 85:132\u2013138","journal-title":"Neurobiol Learn Mem"},{"key":"4346_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","volume":"558","author":"K Rutten","year":"2007","unstructured":"Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A (2007) Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 558:107\u2013112","journal-title":"Eur J Pharmacol"},{"key":"4346_CR43","volume-title":"Nonparametric statistics for the behavioral sciences","author":"S Siegel","year":"1988","unstructured":"Siegel S, Castellan NJ (1988) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York"},{"key":"4346_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuropharm.2007.04.009","volume":"53","author":"JA Siuciak","year":"2007","unstructured":"Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR (2007) Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology 53:113\u201324","journal-title":"Neuropharmacology"},{"issue":"Suppl 3","key":"4346_CR45","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00004850-199803003-00004","volume":"13","author":"CA Tamminga","year":"1998","unstructured":"Tamminga CA, Buchanan RW, Gold JM (1998) The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 13(Suppl 3):S21\u20136","journal-title":"Int Clin Psychopharmacol"},{"key":"4346_CR46","first-page":"55","volume":"5","author":"SD Targum","year":"2008","unstructured":"Targum SD, Keefe RS (2008) Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment? Psychiatry (Edgmont) 5:55\u201359","journal-title":"Psychiatry (Edgmont)"},{"key":"4346_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pnpbp.2010.08.018","volume":"35","author":"Y Ueoka","year":"2011","unstructured":"Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M et al (2011) Quality of life and cognitive dysfunction in people with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35:53\u20139","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4346_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbr.2012.03.023","volume":"232","author":"NP van Goethem","year":"2012","unstructured":"van Goethem NP, Rutten K, van der Staay FJ, Jans LA, Akkerman S, Steinbusch HW, Blokland A, van't Klooster J, Prickaerts J (2012) Object recognition testing: rodent species, strains, housing conditions, and estrous cycle. Behav Brain Res 232:323\u2013334","journal-title":"Behav Brain Res"},{"key":"4346_CR49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/138161210790170085","volume":"16","author":"ML Wadenberg","year":"2010","unstructured":"Wadenberg ML (2010) Conditioned avoidance reponse in the developmetn of new antipsychotics. Curr Pharm Des 16:358\u201370","journal-title":"Curr Pharm Des"},{"key":"4346_CR50","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","volume":"23","author":"ML Wadenberg","year":"1999","unstructured":"Wadenberg ML, Hicks PB (1999) The conditoined avoidance reponse test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychtoics? Neurosci Biobehav Rev 23:851\u201362","journal-title":"Neurosci Biobehav Rev"},{"key":"4346_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S1461145706006638","volume":"10","author":"ML Wadenberg","year":"2007","unstructured":"Wadenberg ML, Wiker C, Svensson TH (2007) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191\u2013202","journal-title":"Int J Neuropsychopharmacol"},{"key":"4346_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1017\/S1461145708008730","volume":"11","author":"C Wiker","year":"2008","unstructured":"Wiker C, Schilstr\u00f6m B, Sandb\u00e4ck C, Wadenberg ML, Svensson TH (2008) Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats. Int J Neuropsychopharmacol 11:845\u2013850","journal-title":"Int J Neuropsychopharmacol"},{"key":"4346_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1523\/JNEUROSCI.3827-04.2005","volume":"25","author":"BD Winters","year":"2005","unstructured":"Winters BD, Bussey TJ (2005) Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. J Neurosci 25:52\u201361","journal-title":"J Neurosci"},{"key":"4346_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/0269881114555252","volume":"29","author":"JW Young","year":"2015","unstructured":"Young JW, Geyer MA (2015) Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol 29:178\u2013196","journal-title":"J Psychopharmacol"},{"key":"4346_CR55","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/sj.npp.1300393","volume":"29","author":"JW Young","year":"2004","unstructured":"Young JW, Finlayson K, Spratt C, Marston HM, Crawford N, Kelly JS, Sharkey J (2004) Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29:891\u2013900","journal-title":"Neuropsychopharmacology"},{"key":"4346_CR56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","volume":"122","author":"JW Young","year":"2009","unstructured":"Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battey for research in schizophrenia. Pharmacol Ther 122:150\u2013202","journal-title":"Pharmacol Ther"},{"key":"4346_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchromb.2005.01.027","volume":"819","author":"M Zhao","year":"2005","unstructured":"Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y et al (2005) Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 819:73\u201380","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4346-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-016-4346-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4346-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4346-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:54:29Z","timestamp":1692406469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-016-4346-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":57,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["4346"],"URL":"https:\/\/doi.org\/10.1007\/s00213-016-4346-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]},"assertion":[{"value":"17 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was supported, in part, by Intra-Cellular Therapies, Inc. (ITI). ITI-214 is an investigational new drug under development by ITI. Drs. Snyder, Zhu, Yao, Li, Zhang, Zheng, Hendrick, Vanover, Wennogle, and Mates were full-time employees of ITI while the experiments were conducted. Dr. Davis was a paid consultant of ITI during the course of these studies and is currently a full-time employee of ITI. Drs. Akkerman and Prickaerts are investigators at Maastricht University, The Netherlands. Dr. Wadenberg was an Associate Professor\/Lecturer at Linnaeus University, Kalmar, Sweden during the conduct of these studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was supported, in part, by funding from the NIH (R43 MH067488-01 to Intra-Cellular Therapies Inc.).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}